Identifying risk for attrition during treatment for depression

Area of Science:

• Psychiatry
• Clinical Psychology
• Pharmacology

Background:

• Major depressive disorder (MDD) treatment persistence is a significant challenge.
• Understanding patient ambivalence towards treatment is key for developing effective retention strategies.

Purpose of the Study:

• To investigate the relationship between patients' pretreatment intentions and their persistence in an 8-week selective serotonin reuptake inhibitor trial for MDD.
• To identify early predictors of attrition in antidepressant treatment.

Main Methods:

• 265 participants with MDD were enrolled in an 8-week trial using a selective serotonin reuptake inhibitor.
• Intent to continue treatment, even with side effects or lack of improvement, was assessed at baseline and week 2.
• Attrition was defined as discontinuation of clinic visits before trial completion.

Main Results:

• A baseline uncertain/negative intent to continue treatment was significantly associated with higher dropout rates by weeks 6 and 8.
• Uncertain/negative intent at week 2 strongly predicted attrition at all subsequent visits.
• Positive intent to continue was linked to better symptom improvement, irrespective of efficacy or dropout status.

Conclusions:

• Pretreatment concerns about antidepressant treatment, particularly regarding side effects, pose a significant barrier to completing the acute treatment phase.
• Individualized assessment of patient concerns and tailored interventions are necessary to mitigate attrition in MDD treatment.
• Addressing patient expectations and potential challenges proactively can improve treatment adherence and outcomes.